faah inhibition ameliorates breast cancer in murine model | oncotarget
Published 1 year ago • 91 plays • Length 2:02Download video MP4
Download video MP3
Similar videos
-
1:06
dr. finn on the potential of cdk inhibition
-
0:53
final results of the phase 3 data trial assessing aromatase inhibition in hr breast cancer
-
1:57
michael hassett, md, mph, on breast cancer treatment | dana-farber cancer institute
-
1:12
dr. fuqua on esr1 mutations in primary breast cancer
-
2:25
reducing risk in residual breast cancer
-
1:45
targeting egfr for the treatment of inflammatory breast cancer
-
48:30
impact of liquid biopsy in advanced her2 breast cancer tumors: a follow-up study
-
6:37
the estrogen-receptor antagonist fulvestrant in breast cancer
-
1:27
q&a "what is the difference between aromatase inhibitors and tamoxifen?"
-
1:18
esmo22: breast cancer research by sara tolaney, md (tropics) | dana-farber cancer institute
-
19:51
cerianna™: seeing deeper into recurrent or metastatic breast cancer | fengting yan, md, phd
-
0:32
treating metastatic breast cancer by diminishing ovarian function
-
28:21
metastatic breast cancer forum 2018: liquid biopsies | dana-farber cancer institute
-
1:06
asco22: breast cancer research by sara tolaney, md | dana-farber cancer institute
-
0:58
dr. davidson discusses breast cancer chemoprevention
-
2:11
hypofractionated radiation therapy for breast cancer
-
6:00
fda weighs possible cancer risks of textured breast implants
-
3:50
overview of recent fda approvals for metastatic hr breast cancer
-
2:37
aromatase inhibitors risk to benefit ratio